Survodutide and Mazdutide: The GLP-1 and Glucagon Research Strategy
Compare GLP-1/glucagon dual-agonist research while separating individual molecules, trial designs, current regional status, and the distinct GIP/GLP-1 tirzepatide strategy.
| Shared targets | GLP-1 and glucagon receptors |
|---|---|
| Survodutide program | SYNCHRONIZE |
| Mazdutide example | GLORY-1 |
| Jurisdiction matters | Mazdutide has a China approval; survodutide remains investigational |
| Catalog comparator | Hero TZ targets GIP/GLP-1, a different dual strategy |
| Hero product | Hero TZ |
Survodutide and mazdutide are separate molecules studied for combined GLP-1 and glucagon receptor activity. Their shared target pair makes them useful examples of one multi-agonist strategy. It does not make their chemistry, study results, or approval status identical.
The comparison also helps clarify the word dual. Tirzepatide combines GIP and GLP-1 activity, while these programs pair glucagon with GLP-1. Naming the receptors is more informative than counting targets alone.
Origin story: a different second receptor
Both survodutide and mazdutide entered clinical development as GLP-1/glucagon receptor dual agonists. Published trials investigate each complete molecule in defined populations. A receptor map explains why the programs are related, but each trial remains its own experiment (le Roux et al., 2026; Ji et al., 2025).
The receptor explainer covers the individual pathways. Here, the useful question is what evidence supports this specific target pairing and how to avoid importing findings from a different dual agonist.
A precise materials description should therefore retain the compound name and target profile. A label such as dual agonist leaves open which receptors are involved, what relative activities were measured, and which preparation supplied the result.
How GLP-1/glucagon dual agonism works
Receptor agonism means activation of a target receptor. A molecule assigned two targets must be characterized at both. That does not imply equal activity at each receptor or establish the balance of downstream signals in a whole organism.
The survodutide and mazdutide trials describe the intended target pairing. They do not, by a body-weight result alone, isolate how much of the outcome came from each receptor. Mechanistic attribution requires experiments designed to separate those contributions (le Roux et al., 2026; Ji et al., 2025).
Tirzepatide supplies a useful contrast because its second incretin target is GIP. Its discovery program investigated that different combination. Findings from tirzepatide should not become evidence for glucagon-receptor activity simply because both approaches are called dual (Coskun et al., 2018).
The single, dual, and triple agonist guide develops the distinction between breadth of targets and strength of a particular response. Both are relevant, but they answer different questions.
Key studies: compare designs before comparing results
| Study | Population and duration | Role in the evidence | Boundary |
|---|---|---|---|
| SYNCHRONIZE-1, survodutide | Adults with obesity or qualifying overweight, without diabetes; 76 weeks | Phase 3 placebo-controlled comparison | Not a direct mazdutide comparison |
| GLORY-1, mazdutide | Chinese adults with obesity or overweight; primary evaluation at 32 weeks, follow-up through 48 weeks | Phase 3 placebo-controlled comparison | Different population and duration |
| Tirzepatide discovery program | Laboratory and early clinical work | Different GIP/GLP-1 strategy | Not interchangeable mechanistic evidence |
SYNCHRONIZE-1 reported mean weight changes of −12.2% and −13.0% in the two survodutide groups versus −5.4% with placebo at 76 weeks under its treatment-regimen estimand. Those results belong to that trial and analysis (le Roux et al., 2026).
GLORY-1 reported reductions in body weight with mazdutide compared with placebo. The primary endpoint timing, population, and treatment groups differ from SYNCHRONIZE-1. Their percentages should not be turned into a direct ranking of the molecules (Ji et al., 2025).
Read the analysis definition as well as the endpoint. An estimate based on a treatment strategy can differ from an estimate assuming continued exposure. A headline that drops this context can make an indirect comparison look more precise than it is.
Also retain adverse events and discontinuations when summarizing efficacy. A group-level weight result does not supply a complete account of tolerability or establish the response expected in each participant.
Weak spots: what we don’t know
As of November 5, 2026, Boehringer Ingelheim describes survodutide as investigational. Mazdutide received China’s NMPA approval for chronic weight management in adults with overweight or obesity in June 2025. That approval should not be described as a global or FDA approval (Boehringer Ingelheim, 2026; Innovent Biologics, 2025).
Shared targets do not establish equal receptor selectivity, exposure, or safety. The complete molecular design and preparation matter. A trial in one population also does not settle outcomes in every other population.
These clinical programs do not validate a supplier’s research stock or imply that either molecule is in Hero’s catalog. Hero TZ appears here only as the catalog comparator for a different dual-receptor strategy.
Finally, a weight-related endpoint cannot by itself prove a specific energy-expenditure or tissue mechanism. Keep the proposed explanation distinct from a directly measured mechanism.
Handling dual-agonist comparisons in the lab
Identify each actual material and document its receptor profile, supplied form, lot, content basis, and assay medium. Keep a GLP-1/glucagon compound distinct from a GIP/GLP-1 comparator in every worksheet.
For catalog-comparator math, a nominal 10 mg tirzepatide sample recovered at a final volume of 2 mL gives 5 mg/mL, or 5,000 mcg/mL. A 0.10 mL analytical aliquot contains a nominal 500 mcg.
That example assigns no preparation conditions to survodutide or mazdutide. Equal masses would not establish equal molar concentrations, receptor occupancy, or biological responses between the different molecules.
Use the reconstitution guide and calculator for arithmetic. Compatibility, stability, and receptor activity still require evidence for the actual material.
Survodutide and mazdutide FAQ
Are these the same molecule?
No. They are separate development programs sharing a receptor-target pairing.
Are they the same dual strategy as tirzepatide?
No. Tirzepatide pairs GIP with GLP-1, rather than glucagon with GLP-1.
Does mazdutide’s China approval establish FDA approval?
No. Regulatory status must retain the jurisdiction and specified product.
What is Hero TZ?
Hero TZ is Hero Peptides’ tirzepatide research material in 10 mg and 30 mg vials. It is not survodutide or mazdutide.
References
- le Roux CW, et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026;395(8):776-787. Source.
- Ji L, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. Source.
- Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. Source.
- Boehringer Ingelheim. New Phase III data in people with obesity and diabetes. Company announcement, October 1, 2026. Source.
- Innovent Biologics. Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China’s NMPA for Chronic Weight Management. June 27, 2025. Source.
For laboratory research use only. Not for human or veterinary use. This article summarizes published research and is not medical advice.